Concepedia

Publication | Open Access

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

DOIFull Paper Access

741

Citations

19

References

2019

Year

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers, Manali Kamdar, Andrew McMillan, Mark Hertzberg, Sarit Assouline, Tae Min Kim, Won Seog Kim, Muhıt Özcan,
Journal of Clinical Oncology

Abstract

Polatuzumab vedotin combined with BR resulted in a significantly higher CR rate and reduced the risk of death by 58% compared with BR in patients with transplantation-ineligible R/R DLBCL.

References

YearCitations

Page 1